What is Lenisna?
Lenisna is presented as a PDLLA-based biostimulator. Its exact composition, manufacturer and registration in Türkiye should be verified from official product documents.
Biostimulators aim to set off a controlled tissue response that encourages collagen production, rather than relying on immediate volume. Lenisna is referred to among the products containing PDLLA. Even products that share an active substance can differ in particle structure, carrier ingredients and preparation, so product-specific details should always be taken from the manufacturer’s instructions for use and registration documents rather than from general descriptions.
This page therefore describes the general characteristics of the PDLLA class and the points considered when a product is assessed, rather than repeating unverified details about Lenisna. Its registration and traceability in Türkiye should be checked before treatment, and you are entitled to see the box, batch number and expiry date. Whether Lenisna or another approach is right for you is decided by the physician at an in-person assessment.
What is PDLLA, and how does it relate to PLLA?
PDLLA is a polymer made from both the L and D forms of lactic acid, placing it in the same family as PLLA. Its structural differences mean it may behave differently in tissue.
Lactic acid exists in two mirror-image forms, known as L and D. PLLA is made only from the L form, whereas PDLLA contains both. This difference can affect the physical structure of the polymer and the way it is broken down in the body. Both polymers are gradually broken down into lactic acid and cleared, and in the process they are intended to stimulate collagen production in the surrounding tissue.
PDLLA-based products are often presented for more superficial, skin-quality-focused use than PLLA products, although this is a general tendency and each product should be assessed on its own documentation. No general ranking between the two classes is possible. Which might suit you better depends on your skin, the area and your goals, and is discussed at an in-person consultation.
What can it address, and what can it not?
It may provide gradual support for skin quality, fine lines and mild volume loss. Significant volume loss, contour change and advanced sagging should not be expected to improve.
Products in the PDLLA class may be considered for changes in skin texture, firmness and overall appearance, and for mild volume loss. Because the effect builds gradually, a course of sessions is usually planned and results are assessed over several months. How much change occurs depends on your collagen response, age and lifestyle. The areas in which it can be used follow the product’s instructions and its registration scope.
For significant volume loss, other classes such as HA fillers or CaHA may be discussed. Marked excess skin and advanced sagging are beyond what injections can address, and PDLLA-based products are not equivalent to a surgical facelift. Use in thin areas such as around the eyes is considered carefully, taking into account the product’s instructions and the risk of nodules, and expectations are set openly at consultation.
Who may not be suitable?
It is not used during pregnancy or breastfeeding, with active infection in the area or with a known allergy to its components. A tendency to keloid scarring and immune conditions need careful assessment.
Treatment is not carried out, or is postponed, during pregnancy and breastfeeding, with active infection, cold sores, an acne flare or inflammatory skin disease in the area, or with a known allergy to any component. Because biostimulators work through a tissue response, a tendency to keloid scarring, active autoimmune disease and treatments that affect the immune system are assessed with particular care. Bleeding disorders and blood thinners are also discussed.
If the product’s composition or registration cannot be confirmed, treatment is not advised. This class may also not suit someone expecting a quick, obvious change or a result equivalent to surgery. Areas previously treated with unknown fillers are assessed separately. All of this is discussed alongside your medical history at an in-person consultation, and a decision can be deferred until any missing information has been obtained.
What does treatment involve, and what are the risks?
Treatment starts with assessment, product verification and planning; several sessions and reviews are usual. Swelling, bruising, nodules and, rarely, vascular occlusion are possible.
On the day, the skin is disinfected and the product is prepared according to its instructions. Avoiding strenuous exercise, saunas, alcohol and pressure on the face for 24 to 48 hours is usually advised. After superficial placement, small raised bumps and redness can be visible for the first few days. Whether massage or other aftercare is needed will be explained to you specifically, and follow-up visits allow the gradual effect to be monitored.
Common effects include swelling, redness, tenderness and bruising. Small nodules under the skin may be noticed weeks or months later, and granulomas can occur rarely. As with any injectable, vascular occlusion is rare but serious and requires urgent assessment. These risks, and what would be done if a problem arose, are discussed in person before any treatment goes ahead.
Frequently asked questions
How are Lenisna and Juvelook related?
Both are referred to as PDLLA-class products; Juvelook is additionally presented as containing hyaluronic acid. The exact composition and manufacturer of each should be confirmed from official documents, and the choice is made at consultation.
How long does Lenisna last?
Duration depends on the product’s composition, the area treated and your metabolism. Without verified product-specific information it would not be accurate to quote a figure; your likely duration is discussed at consultation.
Is Lenisna a filler?
It is presented as a biostimulator, so its main aim is to stimulate collagen rather than add immediate volume. Where significant volume is needed, other product classes may be discussed.
How many Lenisna sessions are needed?
Biostimulators are usually given as a course of several sessions a few weeks apart. The number and interval for Lenisna are set at consultation according to the manufacturer’s documents and your skin’s response.
When does Lenisna start to work?
Lenisna, like other PDLLA-based biostimulators, works gradually: change usually begins over several weeks and becomes clearer in the months after the sessions are complete. The raised bumps and fullness of the first days are a temporary effect of the injections and do not reflect the result. The timeline specific to Lenisna is assessed against the manufacturer’s documents and varies from person to person.
Can Lenisna be combined with salmon DNA (polynucleotides)?
Lenisna and polynucleotide treatments, often called salmon DNA, can be considered within the same skin-quality plan. Whether they are given in the same session or at different times depends on your skin’s needs and each product’s instructions for use. Planning them in separate sessions makes it easier to monitor the effect of each treatment, and any side effects, on its own.
When can I go back to retinol and acid skincare after Lenisna?
After Lenisna, you can usually return to potentially irritating products such as retinol, AHAs and BHAs once redness and bumps have settled and the skin has calmed, often within a few days. Pausing them for a few days beforehand may also reduce sensitivity. If you take, or have recently stopped, an oral retinoid for acne, the timing of Lenisna is planned with this in mind.
Does Lenisna treatment hurt?
For most people, the discomfort of Lenisna treatment is mild to moderate: a brief sting where the needle or cannula enters and a feeling of pressure as the product is placed. Numbing cream is usually applied beforehand. Whether the product can be mixed with a local anaesthetic during preparation depends on Lenisna’s instructions for use. Any tenderness afterwards usually eases within a few days.
This content is for general information and does not replace a personal medical assessment.